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The etiopathogenesis of the irritable bowel syndrome (IBS), 
one of the most prevalent gastrointestinal disorders, is not 
well known. The most accepted hypothesis is that IBS is the 
result of the disturbance of the ‘brain-gut axis.’ Although the 
pathophysiological mechanisms of intestinal dysfunction are 
complex and not completely understood, stress, infections, 
gut flora, and altered immune response are thought to play a 
role in IBS development. The intestinal barrier, composed of 
a single-cell layer, forms a physical barrier that separates the 
intestinal lumen from the internal milieu. The loss of integrity 
of this barrier is related with mucosal immune activation and 
intestinal dysfunction in IBS. The number of mast cells and T 
lymphocytes is increased in the intestinal mucosa of certain 
IBS patients, and the mediators released by these cells could 
compromise the epithelial barrier function and alter nerve 
signaling within the enteric nervous system. The association 
of clinical symptoms to structural and functional abnormali-
ties of the mucosal barrier in IBS patients highlights the 
importance of understanding the physiological role of the gut 
barrier in the pathogenesis of this disorder. This review sum-
marizes the clinical and experimental evidences indicating 
the cellular and molecular mechanisms of IBS symptomatol-
ogy, and its relevance for future translational research. (Gut 
Liver 2012;6:305-315)
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INTRODUCTION
The intestinal epithelial barrier function is a crucial compo-
nent of gut homeostasis as it represents the first line of defence 
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against many insults, such as bacterial and food antigens and 
toxins. Loss of molecular and functional integrity leading to 
disturbed epithelial barrier and subsequent activation of muco-
sal immune responses is closely related to the pathogenesis of 
many intestinal disorders,1,2 including irritable bowel syndrome 
(IBS).
Although reckoned as multifactorial, current understanding 
of IBS origin and underlying mediators and mechanisms is still 
fragmentary, but today IBS is thought to be the result of the 
dysregulation of the interaction between the central and the en-
teric nervous system, the so-called brain-gut axis.3 The mecha-
nisms behind this disturbance are not clear but a plausible 
hypothesis postulates that the breakdown of intestinal epithelial 
barrier’s surveillance is a key mechanism in the development of 
symptoms compatible with IBS. Evidence has evolved from in 
vivo data showing increased intestinal permeability in IBS pa-
tients,4-7 being more pronounced in those diarrhea predominant 
IBS (IBS-D)4 patients (Table 1). In line with these observations, 
converging reports have revealed the presence of low-grade 
inflammation and immune activation8-10 and impaired barrier 
function11-13 in the intestinal mucosa of certain IBS subgroups as 
a leading events in the origin and severity of visceral hypersen-
sitivity and bowel dysfunction in IBS. In these patients, the in-
flammatory infiltrate is dominated by increased populations of 
mast cells9,10 which have been implicated in intestinal epithelial 
barrier dysfunction, mainly through modulation of tight junc-
tion (TJ) proteins, resulting in increased permeability through 
the paracellular pathway in the intestinal epithelium.
In this review we summarize clinical and experimental evi-
dence indicating molecular and cellular mechanisms underlying 
mucosal barrier dysfunction, associated with clinical symptoms 
in IBS.
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INTESTINAL EPITHELIAL BARRIER FUNCTION
The gastrointestinal (GI) tract constitutes one of the largest 
surface areas that is exposed to and interacts with the external 
environment. To assure homeostasis, the intestinal epithelium 
faces a unique challenge to balance the requirements of form-
ing a protective barrier to separate the intestinal lumen from the 
underlying tissue while simultaneously supporting the absorp-
tion of nutrients and water across the epithelial barrier. Several 
immune and nonimmune defense mechanisms have evolved to 
fence off the continuous luminal threats. These mechanisms are 
organized into two coordinated levels of protection and include 
immune (epithelial and immune cells) as well as nonimmune 
components (gut motility, mucus layer, and secretion of water). 
These elements are thoroughly interconnected and defects in 
any of them can result in barrier dysfunction, altered intestinal 
permeability, eventually leading to inflammatory processes.
At the same time, small amounts of antigens are allowed to 
penetrate the epithelial barrier favoring the induction of im-
mune tolerance mechanisms. This transport of molecules from 
the intestinal lumen to the lamina propria can occur through 
two main routes: the paracellular pathway, which involves pas-
sive movement of small molecules (<600 Da) through the space 
between adjacent epithelial cells; and the transcellular pathway, 
which involves both active and passive movement of larger 
molecules across epithelial cell membranes, usually involving 
the action of specific transport channels and endocytotic mech-
anisms mediated or not by specific membrane receptors. 
1. Mucosal barrier components
1) Extracellular components of the intestinal barrier
The intestinal mucosal surface is covered with a layer of mu-
cins and lipids that limit the exposure of the monolayer of in-
testinal epithelial cells to sheer forces and other physical trauma 
from particles within the lumen, and also prevents direct con-
tact of the epithelium with microorganisms.14 The mucus layer 
provides the first protection against luminal microorganisms 
and contributes to the retention of mucosal secretions rich in 
antibacterial peptides (such as cathelicidins and defensins) and 
immunoglobulin A which binds, aggregates, or destroys bac-
teria preventing their adherence to the mucosa and subsequent 
transepithelial invasion.15,16 Emerging evidence have shown that 
defensins are not only required to fight invading pathogens, 
but also participate in modulating microbiota composition and, 
hence, shaping adaptive immune responses.17
In addition, the high turnover of epithelial cells and intestinal 
peristalsis together with massive water secretion in response to 
pathogenic stimulus are also essential factors of the intestinal 
barrier function.
2) Cellular components of the intestinal barrier
The cellular components of the intestinal barrier consist of 
a complex array of cell types present within the epithelium: 
absorptive enterocytes, mucus-producing goblet cells, entero-
endocrine cells that produce peptide hormones and Paneth cells 
involved in secretion of antimicrobial peptides. In addition, both 
innate and adaptive immune cells, mainly T and B lymphocytes, 
immunoglobulin A (IgA)-secreting plasma cells, mast cells, den-
dritic cells, and macrophages are present at steady state and in-
teract together to maintain a balanced immune response against 
intestinal antigens aimed at preserving gut homeostasis.
Intestinal epithelial cells also contribute to the mucosal im-
mune surveillance through the expression of a wide range of 
pattern recognition receptors, such as toll-like receptor (TLR) 
and intracellular nucleotide-binding oligomerization domain 
(NOD)-like receptors.18 Signaling through NODs and TLRs is 
regulated by intestinal microbiota and its activation in entero-
cytes and Paneth cells leads to the expression and release of 
antimicrobial peptides.15 These molecules participate actively in 
the intestinal host-microbial homeostasis reinforcing the barrier 
function. In addition, the enterocytes are able to act as non-
professional antigen presenting cells and communicate to and 
modulate diverse underlying populations of intestinal immu-
nocytes. Indeed, epithelial cells are able to release several che-
mokines and cytokines involved in neutrophil and macrophage 
recruitment (CXC-chemokine ligand [CXCL]-1 and CXCL-2) 
Table 1. Summary of the in vivo and in vitro Assessments of Intestinal Permeability in Patients with Irritable Bowel Syndrome (IBS)
Method No. of IBS patients/controls Result Reference
In vivo 51Cr-EDTA 30 IBS+15 controls Increased small intestinal permeability in IBS-D 4
Lactulose/Mannitol 54 IBS-D+22 controls Increased colonic permeability in 39% of IBS-D 5
Lactulose/Mannitol 31 IBS+12 controls Increased small bowel permeability in IBS 6
Lactulose/Mannitol 132 IBS+86 controls Increased colonic permeability in 36% of IBS vs 19% of controls 7
Lactulose/Mannitol 19 IBS-D+10 controls Increased small intestinal permeability in 42% of IBS-D 85
In vitro Ussing chambers 12 IBS+5 controls Increased permeability of colonic biopsies from IBS, no differences when 
subgroups were analyzed
11
Ussing chambers 52 IBS+25 controls Supernatant from IBS-D increased permeability in mice colonic samples 79
EDTA, ethylenediaminetetraacetic acid;  IBS-D, diarrhea-predominant irritable bowel syndrome.
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and in the regulation of the inflammatory potential of dendritic 
cells (thymic stromal lymphopoietin). Furthermore, recognition 
of bacteria through TLRs could also account for the production 
of CD40-independent IgA class switch recombination-inducing 
signals such as B-cell activating factor of the tumor necrosis 
factor (TNF) family and proliferation-inducing ligand by epithe-
lial cells. The dysregulation of this immunomodulatory function 
of the intestinal epithelial cells might contribute to both, the loss 
of tolerogenic mechanisms and the induction of inflammatory 
responses, ultimately leading to the development of intestinal 
inflammation.19
2. The apical juntional complex
The epithelial cells within the intestinal epithelium form 
a continuous, polarized monolayer where the individual cell 
membranes are connected together through the apical junc-
tional complex. This intercellular complex is composed of TJ, 
adherens junctions, and desmosomes, as well as gap junctions 
for cell-to-cell communication (Fig. 1).
1) TJs
Intestinal permeability to small, water-soluble molecules is 
determined by TJs, which seal the paracellular spaces between 
the epithelial cells lining the lumen of the gut. TJs are the major 
constituents of the apical junctional complex, located at the 
most luminal site of the epithelium. TJs act as both a gate that 
limits the paracellular transport of ions and the translocation of 
luminal antigens (microorganisms and their toxins), and a fence 
that separates the plasma membrane into the apical and baso-
lateral domains.1
TJs are multi-protein complexes composed of transmembrane 
proteins (occludin, claudins, and junctional adhesion molecule) 
and peripheral membrane (scaffolding) proteins (zonula oc-
cludens [ZO]) (Fig. 2). The structural and functional integrity of 
the TJ depends on the presence of a peri-junctional ring of actin 
and myosin, which also contributes to the regulation of para-
cellular permeability. Indeed, contraction of the peri-junctional 
cytoskeleton induced after phosphorylation of myosin light 
chain (MLC) has been shown to lead to enhanced permeability 
in intestinal epithelia.20 It is believed that the tension resulting 
from this contraction is transmitted to the lateral membranes of 
adjacent epithelial cells perturbing, thereby, TJ barrier function.
Occludin was the first transmembrane protein to be dis-
covered at the TJ; however, its function is not yet fully delin-
eated. Despite occludin being an important constituent of TJs, 
in occludin knockout animals, TJ assembly and paracellular 
permeability remained unchanged.21,22 However, a detailed 
characterization suggested that occludin play a role in the regu-
lation of TJ integrity rather than in the de novo assembly of 
the TJ.21 Furthermore, in vitro data suggests that TJ assembly, 
transepithelial resistance, and localization of occludin to the TJ 
are regulated by phosphorylation.23,24 In homeostasis, occludin 
is highly phosphorylated on Ser and Thr residues, while phos-
phorylation of Tyr residues is kept at minimum. This hyperphos-
phorylated occludin is selectively located at the TJ. However, 
during the disruption of TJs, in response to various stimuli, oc-
cludin undergoes dephosphorylation at Ser/Thr residues, which 
results in redistribution of the protein from the membrane to 
the cytoplasm.24 The precise role of Tyr-phosphorylation in TJ 
disruption is not clear at present, but it has been suggested that 
it may attenuate the interaction between occludin and ZO pro-
teins, leading to the disruption of the TJ.25
Fig. 1. The apical junctional complex. Transmission electron micro-
graph showing the apical junctional complex (AJC) between two ad-
jacent enterocytes in the human jejunal mucosa. Just below the base 
of the microvilli (Mv), the plasma membranes of adjacent cells are in 
intimate contact at the tight junction (TJ), followed by the adherens 
junction (AJ) and desmosomes (D). Bar, 1 mm; amplified area bar, 150 
nm.
Fig. 2. Molecular components of the tight junction. Tight junctions 
are composed of integral transmembrane proteins (claudins, occludin 
and junctional adhesion molecules [JAM]-A, -B and -C) that interact 
in the paracellular space with proteins on adjacent cells. These trans-
membrane proteins are connected to the actomyosin cytoskeleton 
filaments through scaffolding proteins (zonula occludens [ZO] [ZO-1, 
ZO-2, and ZO-3]).
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The observation that barriers can develop in the absence of 
occludin22 prompted a continued search of essential barrier-
forming components of the TJ leading to the identification of 
the claudin family of transmembrane proteins, which consists 
of 24 members between 20 and 27 kDa in size. Claudins play 
a central role in the coordination of barrier function and their 
differential expression and properties appear to determine the 
tissue-specific variations in electrical resistance and paracellular 
ionic selectivity.26 The functional characterization of single clau-
dins has identified specific contributions to the barrier properties 
in the different epithelia of the organism. Some claudins form 
pores that allow preferential passage of specific ions, while other 
claudins contribute to strengthening the barrier by preventing 
the passage of specific ions (Table 2). Within the intestine, the 
ion-selective properties of the paracellular barrier vary consid-
erably between the individual segments due to their specific 
physiological function showing an overall decrease in perme-
ability towards the distal ends of the GI tract.27 Similarly, the 
ability of intestinal epithelial TJ to discriminate and restrict pas-
sage of solutes based on size varies along the crypt-villus axis.28 
At the molecular level, this is achieved thanks to the segment-
specific expression of different claudins (Table 2). Thus, barrier 
properties along the intestinal epithelium, and along the crypt-
villus axis, are in accordance with the localization of claudins. 
Studies in the human intestine have revealed the expression of 
tightening claudin-1, -3, -4, -5, and -7 in the ileum and colonic 
mucosa,29,30 with barely detectable expression of the permeabil-
ity mediator claudin-2 restricted to the colonic crypts.30,31 How-
ever, claudin-2 expression has been detected in both, the crypt 
and the villus of the small bowel.31 This change in the expres-
sion and distribution of claudins may respond to the specific 
physiological function carried out by the intestinal epithelium 
along the intestine, as it has to guarantee the absorption of fluid 
and nutrients in the small bowel while protecting against a vast 
amount of luminal antigens from the resident microbiota in the 
colon.
The TJ transmembrane proteins, claudins and occludin, are 
structurally associated to the cytoskeleton, and are composed 
of actin, myosin II and other proteins, through the scaffolding 
proteins ZO.32 This association to the peri-junctional actomyosin 
ring, which encircles the cell at the apical surface, is crucial for 
the dynamic regulation of paracellular permeability. Interest-
ingly, simultaneous elimination of ZO-1 and ZO-2 expression 
prevents claudin recruitment, TJ formation and development of 
epithelial barrier function.33
Although a large number of other TJ-associated proteins have 
been also identified, the manner by which they interact to form 
the selectively permeable barrier is not fully defined. Alterations 
in these structural and regulatory TJ proteins have been linked 
to barrier dysfunction and increased intestinal permeability in 
response to a broad range of inflammatory and infectious stim-
uli.1 However, the molecular mechanisms by which TJ-related 
proteins alter paracellular permeability in specific intestinal dis-
eases require further investigation.
INTESTINAL PERMEABILITY REGULATION 
Far from being a static element, the epithelial barrier function 
is incredibly dynamic and functionally responsive to several 
physiologic, pathologic, and pharmacologic stimuli. Thus, the 
intestinal TJ are constantly being restructured by dietary factors, 
neuro-humoral signaling, inflammatory mediators and a variety 
of cellular signaling pathways which, in turn, are susceptible of 
being usurped by pathogenic bacteria to gain access to the in-
testinal mucosa.22
Regulation of intestinal permeability involves different func-
tional pathways. Fast changes in permeability occur via MLC 
kinase (MLCK)-mediated cytoskeleton contraction and by en-
docytosis of TJ proteins,34,35 whereas more lasting permeability 
disturbances involve the transcriptional modulation of TJ pro-
teins, epithelial cell apoptosis and structural alterations in the 
epithelium.36
MLCK is a Ca2+-calmodulin-dependent Ser-Thr kinase that 
specifically phosphorylates MLC in response to both physiologi-
cal and pathological stimuli.37,38 Phosphorylation of MLC results 
in a conformational change that triggers the contraction of the 
actomyosin cytoskeleton leading to epithelial barrier dysfunction. 
In addition, MLCK activity is also involved in the endocytosis 
of occludin in response to the pro-inflammatory mediator TNF. 
This TNF-induced occludin internalization has been reported to 
be specifically mediated by caveolae endocytosis highlighting 
the role of vesicular traffic pathways in intestinal TJ regulation 
in response to cytokine-mediated barrier dysfunction.39
In vivo functional assessment of the intestinal epithelial bar-
Table 2. Functional Classification of the Claudin Family of Proteins 
and Their Specific Expression Pattern in the Human Gut
Function Claudin Small bowel29,31 Large bowel30,31
Barrier builders Claudin 1 Yes Yes
Claudin 3 Yes Yes
Claudin 4 Yes Yes
Claudin 5 Yes Yes
Claudin 8 No data Yes
Claudin 11 No data Not detectable
Claudin 14 No data Not detectable
Claudin 19 No data No data
Claudins mediating 
permeability
Claudin 2 Yes Restricted to crypts
Claudin 10 No data No data
Ambiguous  
function
Claudin 7 Yes Yes
Claudin 12 No data Not detectable
Claudin 15 Yes Not detectable
Claudin 16 Not detectable Not detectable
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rier can be achieved by measuring differential permeability 
of the intestinal mucosa to nonabsorbable molecular markers, 
including monosaccharides and disaccharides, along the crypt-
villus axis (Table 1).40 Moreover, the physiological properties of 
the paracellular gap can also be accurately assessed in vitro by 
measuring the transepithelial electrical resistance and ionic dif-
fusion potentials, and by quantifying the flux of either labeled 
or electron-dense tracer molecules of various sizes.41 Using both 
approaches, several reports have shown that abnormal intestinal 
permeability characterizes several chronic inflammatory disor-
ders in which this phenomenon has been connected to the dis-
appearance of key structural proteins of the intestinal epithelial 
barrier.42 Although altered intestinal permeability has also been 
reported in a subset of patients with IBS4-7 and the grade of bar-
rier defect related to the onset of symptoms,43 the mechanisms 
responsible and the mediators remain mostly ignored.
A complete discussion of all the mechanisms involved in the 
regulation of intestinal permeability is beyond the scope of this 
article but a few deserve closer attention as they are important 
in our current understanding of IBS pathogenesis (Table 3).
REGULATION OF INTESTINAL BARRIER FUNCTION IN 
IBS
1. Stress-induced intestinal barrier dysfunction
Stress, either physical or psychological, represents a threat 
to the internal homeostasis. In response to stress, a coordinated 
autonomic, endocrine, and immune response is generated to 
maintain stability. However, excessive stress exposure, in sus-
ceptible individuals, impairs this adaptive response, eventually 
predisposing those subjects to the development of new diseases 
or to the exacerbation of previously existing ones.44 This may 
be the case of IBS as epidemiological, empirical, and clinical 
observations have related stressful or traumatic life events with 
symptom onset, severity, and persistence in certain IBS sub-
types.45 In fact, around 50% of IBS patients present comorbidity 
with psychiatric disorders, commonly anxiety and depression,46 
and suffer more chronic stress than the healthy population.10
The core system of the stress response involves the hypotha-
lamic-pituitary-adrenal (HPA) axis and the sympathetic branch 
of the autonomic nervous system. The latter mediates brain-gut 
communication through the enteric nervous system, modulating 
and coordinating GI motility, secretion, and immune function. 
The release of corticotropin releasing factor (CRF) from the hy-
pothalamus in response to activation of the HPA promotes the 
synthesis of corticotropin in the pituitary gland, which stimu-
lates the adrenal cortex to release cortisol that finally circulate 
in the blood reaching every tissue and facilitating the coordina-
tion of brain and peripheral functions. The effects of stress on 
gut function are universal; however, IBS patients appear to have 
enhanced reactivity to stress compared to healthy subjects re-
garding to intestinal motility, sensitivity and permeability, and 
Table 3. Summary of the Cellular and Molecular Alterations That Affect the Intestinal Barrier Function in IBS
Findings in IBS patients Possible mechanism of barrier dysfunction Reference
Cellular alterations Increased CD4/CD3 T-lymphocytes in the intesti-
nal mucosa
MLCK-mediated MLC phosphorylation and 
redistribution of TJ proteins in response to 
TNF-a and IFN-g
6, 9, 10, 60, 62, 63
Increased density and activation of mast cells in 
the intestinal mucosa
Modulation of TJ proteins through tryptase-me-
diated activation of PAR-2 in epithelial cells
9, 10, 12, 55, 57, 66
Increased density of eosinophils in the colonic 
mucosa 
Occludin down-regulation induced by MBP 75, 76
Molecular alterations Down-regulation and redistribution of ZO-1 in 
both the jejunal and colonic mucosa
Impaired claudin recruitment, TJ formation and 
development of barrier function
11, 13, 33
Proteasome-mediated occludin degradation in 
the colonic mucosa
Increased proteasome activity induced by pro-
inflammatory cytokines resulting in loss of TJ 
integrity
12
Redistribution of ZO-1 and increased intestinal 
permeability in mice colonocytes treated with 
fecal supernatants from IBS-D
Impaired claudin recruitment, TJ formation and 
development of barrier function
33, 79
Increased MLC phosphorylation in mice colono-
cytes treated with fecal supernatants from IBS-
D
Contraction of the peri-junctional cytoskeleton 
and enhanced paracellular permeability
79
Up-regulation of miR-29a in both small and 
large bowel of IBS-D
Down-regulation of glutamine sinthetase ex-
pression
85
Reduced claudin 1 and claudin 4 protein levels 
in both small and large bowel mucosa of IBS-D
Weakening of the barrier function 87
IBS, irritable bowel syndrome; MLCK, myosin light chain kinase; MLC, myosin light chain; TJ, tight junction; TNF-a, tumor necrosis factor alpha; 
IFN-g, interferon gamma; ZO, zonula occludens; PAR-2, protease-activated receptor 2; MBP, major basic protein; IBS-D, diarrhea-predominant ir-
ritable bowel syndrome.
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HPA axis hormone levels.47
In the GI tract, the stress-induced mucosal barrier impairment 
is critical for the development of mucosal inflammation. Indeed, 
both acute and chronic stress, have been shown to increase ion 
and water secretion and intestinal permeability in the jejunum 
and the colon of laboratory animals.48-50 These changes were 
paralleled by a marked increase in epithelial macromolecular 
permeability48 and were mimicked by the intraperitoneal injec-
tion of CRF through mast cells and neural pathways.48,51 In addi-
tion, studies using segmental perfusion techniques in the human 
jejunum have revealed that acute stress, either psychological 
or physical, reduced net water absorption52 or increased secre-
tion.53 Moreover, in healthy volunteers, an excessive exposure 
to stressful life events determines an abnormal jejunal epithelial 
response to incoming acute stressful stimuli.54 This abnormal 
response indicates the loss of regulatory mechanisms and may 
represent an initial step in the development of prolonged mu-
cosal dysfunction, a finding that could be linked to IBS etiopa-
thology.
2. Cellular mechanisms of intestinal barrier function in IBS
Although epithelial cells represent the primary cellular de-
terminant of the epithelial barrier function, in the GI tract the 
properties of the intestinal barrier are not intrinsic to epithelial 
cells but also induced by interactions with the immune tissue 
(Fig. 3). Immune cells are associated with the physical barrier to 
provide immunity at entry sites. In the GI tract, immune cells 
reside both within the epithelium and in the lamina propria and 
their movement into the gut lumen is regulated to preserve ho-
meostasis and to avoid inflammation in response to microbial-
associated inflammatory stimuli and to induce tolerance toward 
food antigens.55
A growing number of independent studies have revealed a 
mucosal pathobiological substrate, a process of low-grade in-
flammation and immune activation, common to the intestine of 
certain IBS subgroups.8,9 Notably, the inflammatory infiltrate is 
dominated by mast cells and T lymphocytes,10,56 cells that have 
been largely implicated in stress and infectious intestinal barrier 
dysfunction, and in the generation of intestinal motor abnor-
Fig. 3. Neuro-immune regulation of intestinal barrier function. In the intestinal mucosa, mast cells are strategically located in close proximity to 
epithelial cells and nerve endings, establishing a bidirectional communication through the release of specific mediators. In addition, mast cells 
can recruit and activate other immune cells. The interaction of all these elements is crucial to assure an appropriate intestinal barrier homeostatic 
balance. However, chronic stimulation and the consequent release of inflammatory mediators may lead to tight junction disruption and intestinal 
barrier dysfunction through myosin light chain kinase-mediated phosphorylation of myosin light chain and subsequent changes in the expression 
and localization of tight junction proteins. 
IL, interleukin; IFNg, interferon gamma; TNF-a, tumor necrosis factor alpha; NGF, nerve growth factor; CRF, corticotropin releasing factor; SP, 
substance P; ZO, zonula occludens.
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malities and visceral pain in IBS.57-59
1) T lymphocytes
T cells are involved in adaptive immunity and display many 
functions, including the activation of other cell types, such as 
B lymphocytes and macrophages and the killing of infected 
host cells. Increased density of CD4+ T-cells and CD3+ or CD8+ 
intraepithelial T-cells have been reported along the intestinal 
mucosa of IBS patients.6,9,10,60
T cell-derived pro-inflammatory interleukins (ILs) and cyto-
kines have been implicated in the disruption of intestinal epi-
thelial barrier. TNF-a and interferon gamma (IFNg) have been 
shown to be key effector molecules in the dysregulation of both 
the transcellular and the paracellular pathways through several 
mechanisms including impairment of Na+ absorption and Na+-
glucose co-transport and TJ disruption.61 Both mediators have 
been shown to increase the expression and activity of MLCK 
leading to increased MLC phosphorylation and cytoskeleton 
contraction.62 Moreover, IFNg has been also implicated in the 
redistribution of transmembrane TJ proteins occludin, claudin 
1, and claudin 4.63 Notably, IL-4 and IL-13 have been shown to 
increase intestinal permeability by inducing apoptosis of epithe-
lial cells and regulating claudin 2 expression.64,65
2) Mast cells 
Mast cells are common residents of the intestine, which are 
part of the innate immune system and contribute to the modu-
lation of a wide variety of GI pathophysiological processes.66 
Mast cells have been widely studied in IBS and shown to be 
increased in number9,10,55 and activation10 and directly related to 
the generation of visceral hypersensitivity and abdominal pain 
in IBS.57,58 Moreover, proximity of mast cells to enteric nerves 
has been identified in the colonic mucosa of IBS patients.55 This 
anatomical relationship provides a physical substrate for bidi-
rectional communication between the central nervous system 
and the gut, by which stress, luminal bacteria and other regula-
tory factors may influence GI function and inflammation.65 In 
fact, mast cells respond to neuropeptides and neurotransmitters 
(among other molecules) and synthesize and secrete molecules 
that modulate neural responses as well (CRF, substance P, sero-
tonin, nerve growth factor, etc.).65
Mast cells have been largely implicated in the modulation of 
paracellular permeability. Upon activation they release potent 
inflammatory mediators, including prostaglandins, leukotriens, 
platelet-activating factor, cytokines (TNF-a, IL-3, IL-4, IL-5, IL-
6, and the granulocyte and monocyte colony-stimulating factor) 
and specific proteases (tryptase, chymase, carboxypeptidase-
A).67,68 Among all these mediators, tryptase seems particularly 
relevant as it can activate protease-activated receptor 2 on epi-
thelial cells, resulting in modulation of TJ proteins and increase 
in permeability through paracellular pathways in the intestinal 
epithelium.57,66 Noteworthy, increased tryptase mucosal expres-
sion13,57 and release to the intestinal lumen10 has been recently 
described in IBS patients.
In the GI tract, mast cells play a major role in stress-induced 
regulation of epithelial, motor, and visceral responses.65 In ad-
dition to pro-inflammatory mediators, human mucosal mast 
cells produce and respond to key molecules mediating the stress 
response such as CRF and related peptides (urocortin).69,70 Ac-
tivation of these receptors on the cell surface leads to mast cell 
degranulation and selective release of cytokines and other pro-
inflammatory mediators resulting in altered intestinal barrier 
function.68 Pharmacologic inhibition of mast cells and treatment 
with CRF antagonists have been shown to inhibit the effect of 
mast cell-mediated changes in colonic epithelial physiology in 
animal models.47,71
3) Monocytes/Macrophages 
Monocytes and macrophages trigger an acute inflammatory 
response to infectious agents. Activated macrophages release 
pro-inflammatory cytokines including TNF-a, IL-1b, and IL-6 
which are involved in the recruitment of other inflammatory 
cells and in intestinal barrier dysfunction.61,72,73 The number of 
resident macrophages in the intestinal mucosa of IBS patients 
has been assessed with discrepant results. One study has re-
ported unchanged infiltration of macrophages in the colonic 
mucosa of IBS as compared to healthy individuals,74 while other 
showed reduced number in the mucosa of the rectum of patients 
that developed IBS after a bout of gastroenteritis compared to 
asymptomatic controls.6 This reduction in the macrophage pop-
ulation in IBS patients is further supported by decreased expres-
sion of the macrophage-recruiting chemokines CC-chemokine 
ligand 2 and CXCL10.6
4) Eosinophils
Eosinophils are multifunctional leukocytes implicated in the 
pathogenesis of numerous inflammatory processes, including 
infection, asthma and GI disorders. Eosinophils are also resident 
cells throughout the GI tract (excluding the squamous mucosa 
of the esophagus) and can synthesize and store potent immu-
nologic mediators. Among these mediators, major basic protein 
has been described to induce epithelial barrier dysfunction as-
sociated with the down-regulation of occluding.75 It has recently 
been identify increased number of eosinophils along with mu-
cosal hyperplasia and lymphocyte aggregation in the lamina 
propria of the colon in IBS patients;76 however, this finding has 
not yet been linked to the pathophysiology of IBS. Interestingly, 
eosinophilic cationic protein and eotaxin-1 have been shown to 
be released in the intestinal lumen of IBS patients after CRF in-
jection,77 uncovering a putative role of stress-mediated eosino-
phil activation in IBS physiopathology.
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3. Molecular mechanisms of intestinal barrier function in 
IBS 
Although clinical studies have shown that increased intestinal 
permeability occur along the whole intestine, studies aimed at 
unraveling the molecular basis of this phenomenon in IBS are 
mainly focused on the large bowel. In this sense, application of 
high throughput technologies such as microarray gene profiling 
of mucosal samples from IBS patients are providing meaning-
ful insights on the complex network of molecular interactions 
regulating the intestinal barrier function and its relation to IBS 
clinical manifestations. Indeed, colonic transcriptomic signatures 
of IBS patients have reported significant changes in the expres-
sion of a wide variety of genes involved in the impairment of 
mucosal immune response to microbial pathogens.78 Moreover, 
increased expression of genes involved in production of mucins 
(MUC20) have been found in the colon of IBS suggesting altered 
mucus composition;76 however, the potential implication of this 
finding in IBS pathophysiology remains unclear. Recently, dif-
ferential gene expression patterns of jejunal biopsies from IBS-
D patients have been linked to pathways involved in mast cell 
activation, intestinal permeability and TJ signaling.13
Barrier dysfunction in IBS has been linked to the down-
regulation of the TJ scaffolding protein ZO-111 and proteasome-
mediated occludin degradation in the colonic mucosa of IBS 
patients.12 Down-regulation and redistribution of ZO-1 linked 
to mast cell activation and disturbed bowel habits has been also 
described in the jejunal epithelium of IBS-D patients.13 Interest-
ingly, the same effect on ZO-1 localization together with en-
hanced phosphorylation of MLC resulting in increased intestinal 
permeability has been found in mouse colonocytes added with 
fecal supernatants from IBS-D.79 Given that tryptase, the most 
abundant serine proteases in the mast cells, alters ZO-1 distribu-
tion, associated with increased paracellular permeability in colo-
nocytes,66 it can be speculated that the clinical manifestations 
of IBS-D may rely on mast cell-related impairment of jejunal TJ 
function.
Besides protein down-regulation, structural and functional 
modulation of barrier function can be also achieved by endocy-
tosis of TJ proteins by a mechanism that depends on the stimu-
lus involved.34 Pro-inflammatory factors such as TNF and bac-
terial products have been shown to induce the internalization of 
ZO-1 and occludin by caveolar-mediated endocytosis38 together 
with a concomitant loss of barrier function. Notably, caveolar-
mediated endocytosis has been identified as the most significant 
signaling pathway associated with the transcriptional signature 
of IBS-D in the jejunum.13 Taken together, these results sug-
gest that ZO-1 down-regulation and redistribution may help to 
explain the increased intestinal permeability observed in IBS-D, 
although further studies are needed to define the mechanisms 
and functional consequences of this alteration.
The major focus of attention in above efforts has been the 
characterization of expression of protein-coding genes and 
their use for determining clinical outcomes. However, the ma-
jority of the human genome consists of non-protein-coding 
RNA (ncRNA).80 Increasing evidence points to an important 
functional or regulatory role of ncRNA in cellular processes as 
well as a contribution of aberrant ncRNA expression to disease 
phenotypes.81 These ncRNAs appear to function by the targeting 
of different epigenetic regulatory complexes to their intended 
targets.82 Among the different species of ncRNAs, microRNAs 
(miRNAs) have been identified as playing a fundamental role in 
differentiation, survival and function of immune cells, cytokine 
responses as well as intracellular signaling pathways.83,84 It has 
recently been shown shown that IBS-D patients harbour a dis-
tinctive miRNA profiling,85 which reflects an elevated transcrip-
tion regulation activity that may account for some of the patho-
logical hallmarks observed in this disorder, i.e., distorted barrier 
function, low-grade inflammation and immune activation. 
Small bowel and colon tissues of IBS-D patients with increased 
intestinal permeability showed a consistent molecular profile 
defined by up-regulation of miR-29a and down-regulation of 
glutamine synthetase expression, when compared to healthy 
and IBS-D with normal permeability. Noteworthy, the expres-
sion of miR-29a has been found increased in the colon of ulcer-
ative colitis patients, a disorder also associated with increased 
barrier permeability, though, on the contrary, its expression was 
nonsignificantly altered in a small control population of IBS 
patients.86 It should be equally noted that miR-29a has over 1,100 
estimated targets, whose contribution to the effect of miR-29a 
on intestinal permeability cannot be excluded. One of such pu-
tative targets is the TJ core protein claudin-1. Intriguingly, the 
intestine of IBS-D patients show decreased claudin-1 and clau-
din-4 protein levels in both the mucosa of the small bowel and 
the colon, whereas elevated claudin-1 and claudin-3 levels are 
found in constipated IBS patients.87 These facts support a role 
for miR-29a in controlling gut inflammation and permeability, 
but also bring into question its specific utility as a diagnostic 
marker or therapeutic target for just only IBS-D patients with 
increased permeability.
CONCLUSIONS
Recent studies conducted in IBS patients provide strong 
evidence for the presence of low-grade inflammation together 
with altered intestinal permeability; however, whether one phe-
nomena precedes the other remains to be established. Stress or 
bacterial-mediated disruption of epithelial barrier function in 
IBS may result in adaptive neuro-immunological responses that, 
together with the malfunctioning of inflammation tuning-down 
mechanisms may lead to longstanding increase of gut perme-
ability and hypersensitivity. The TJ is a critical determinant of 
mucosal barrier function. In the absence of mucin deficiency 
or gross epithelial damage, the TJ is the primary determinant 
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of paracellular permeability. Defining how TJ-associated mol-
ecules are regulated and how they signal to modulate changes 
in epithelial cells in IBS would be essential to understand their 
contribution to the pathogenesis of this disorder.
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